Recent News

• 09.17.2025 - Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
• 09.16.2025 - Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
• 08.31.2025 - Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
• 08.30.2025 - Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
• 08.27.2025 - Cytokinetics to Participate in September Investor Conferences
• 08.25.2025 - Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
• 08.20.2025 - Cytokinetics Names Jim Daly to Board of Directors

Recent Filings

• 09.16.2025 - 8-K Current report
• 09.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.08.2025 - 8-K/A Current report
• 09.03.2025 - EX-99.1 EX-99.1
• 09.03.2025 - 8-K Current report
• 09.02.2025 - 8-K Current report
• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 144 Report of proposed sale of securities
• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities